Since the development and application of MDM2 inhibitors in cancer therapy, the target PTEN‐MDM2‐p53‐p21 pathway has become increasingly important in clinical therapy for pancreatic cancer. Here, CDKN1A is linked to familial pancreatic carcinoma.